AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12941063 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 51
Study 12941063 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg
Number of subjects: 51
Study 12941063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12941063 — intervention group
Group type: EXPERIMENTAL
Intervention: All three compounds (Climodien, Estradiol valerate, Placebo)
Number of subjects: 51
Study 10653047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 34
Study 10653047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8787364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular diphtheria/pertussis/tetanus (ADPT) vaccines
Number of subjects: 1182
Study 8787364 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell diphtheria-pertussis-tetanus (WCDPT) vaccine
Number of subjects: 1182
Study 1832906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 172
Study 1832906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin and 5‐fluorouracil (CAF)
Number of subjects: 172
Study 1832906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitolactol (dibromodulcitol), doxorubicin and vincristine alternating after every three cycles with three cycles of CMF (DAV/CMF)
Number of subjects: 172
Study 4067975 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemarthrosis aspiration
Number of subjects: 14
Study 4067975 — intervention group
Group type: COMPARATOR
Intervention: Non-aspiration
Number of subjects: 14
Study 29384705 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing intervention based on motivational interviewing (MI)
Number of subjects: 28
Study 29384705 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 28
Study 26782313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity treadmill walking exercise
Number of subjects: 14
Study 26782313 — intervention group
Group type: COMPARATOR
Intervention: Seated quiet rest
Number of subjects: 14
Study 24555753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin
Number of subjects: 43
Study 24555753 — intervention group
Group type: COMPARATOR
Intervention: Low-dose clarithromycin
Number of subjects: 43
Study 23876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 78
Study 23876282 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (rhythm pedagogic program)
Number of subjects: 78
Study 21654616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 30
Study 21654616 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound Therapy (US)
Number of subjects: 30
Study 18474151 — intervention group
Group type: EXPERIMENTAL
Intervention: Jessner's solution
Number of subjects: 60
Study 18474151 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% salicylic acid
Number of subjects: 60
Study 17136873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine plus pseudoephedrine (C+P)
Number of subjects: 51
Study 17136873 — intervention group
Group type: COMPARATOR
Intervention: Loratadine plus pseudoephedrine (L+P)
Number of subjects: 51
Study 14578243 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 756
Study 14578243 — intervention group
Group type: COMPARATOR
Intervention: Human NPH insulin
Number of subjects: 756
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (group K)
Number of subjects: 28
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (group P)
Number of subjects: 28
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (group C)
Number of subjects: 28
Study 11054327 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group C with group P
Number of subjects: 28
Study 11054327 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group C with group K
Number of subjects: 28
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement in visual acuity
Number of subjects: 28
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to improvement
Number of subjects: 28
Study 11054327 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity and fluorescein angiography
Number of subjects: 28
Study 8627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (TNF-alpha, IL-6, IL-8) and counterinflammatory compounds (IL-10, sTNFR-55, sTNFR-75) levels
Number of subjects: 38
Study 8627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between appearance of petechiae and blood sampling
Number of subjects: 38
Study 8627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor (PAI)-1 levels
Number of subjects: 38
Study 1471279 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback and cheek taping, 2-3 times a week, each session of 15 minutes
Number of subjects: 35
Study 1471279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study 1471279 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (both intervention and control)
Number of subjects: 35
Study 1471279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right-sided facial palsy
Number of subjects: 35
Study 1471279 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire about emotional reactions
Number of subjects: 35
Study 6588975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate 1 g b.i.d.
Number of subjects: 5
Study 6588975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 3 g/day (b.i.d. or t.i.d.)
Number of subjects: 5
Study 6588975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 3.0 g/day (alternate to previous schedule) and gemfibrozil 1.2 g/d in divided doses
Number of subjects: 5
Study 31711464 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles Vaccination (MV)
Number of subjects: 28000
Study 31711464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccination (OPV)
Number of subjects: 28000
Study 31711464 — intervention group
Group type: COMPARATOR
Intervention: Health check-up
Number of subjects: 28000
Study 30462765 — intervention group
Group type: EXPERIMENTAL
Intervention: Family religiosity (measured by frequency of religious practice)
Number of subjects: 1134
Study 26463708 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 303
Study 26463708 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 303
Study 24708204 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1)
Number of subjects: 118
Study 24708204 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) abatacept (∼10 mg/kg monthly)
Number of subjects: 118
Study 24708204 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) abatacept
Number of subjects: 118
Study 24708204 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) abatacept
Number of subjects: 118
Study 22198427 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin bronchoscopic method
Number of subjects: 203
Study 22198427 — intervention group
Group type: COMPARATOR
Intervention: Guide sheath method
Number of subjects: 203
Study 20426797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) day(‐1) for 30 days
Number of subjects: 0
Study 20426797 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study 20426797 — intervention group
Group type: COMPARATOR
Intervention: Control group (gallbladders removed for neoplastic diseases)
Number of subjects: 0
Study 17285422 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannula (WGC)
Number of subjects: 100
Study 17285422 — intervention group
Group type: COMPARATOR
Intervention: Non-wire-guided cannula (non-WGC)
Number of subjects: 100
Study 17285422 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannula (WGC) among less experienced operators
Number of subjects: 100
Study 17285422 — intervention group
Group type: COMPARATOR
Intervention: Non-wire-guided cannula (non-WGC) among less experienced operators
Number of subjects: 100
Study 15591329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 180
Study 15591329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 180
Study 15591329 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 180
Study 11871383 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain-formulated aspirin (PF)
Number of subjects: 6
Study 11871383 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (EX2)
Number of subjects: 6
Study 11871383 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (EX5)
Number of subjects: 6
Study 11871383 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release formulations (EX2 and EX5)
Number of subjects: 6
Study 10470743 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+GLA
Number of subjects: 146
Study 10470743 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 146
Study 8561282 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks to attain a breath alcohol level of 0.10
Number of subjects: 21
Study 8561282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2350476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita-Stat automatic blood pressure recorder
Number of subjects: 518
Study 2350476 — intervention group
Group type: COMPARATOR
Intervention: Random-Zero sphygmomanometer
Number of subjects: 518
Study 94176 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (SCT) 3 x 20 micrograms = 300 MRCU intravenously for 6 days
Number of subjects: 94
Study 94176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 31975479 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible visitation policy
Number of subjects: 60
Study 31975479 — intervention group
Group type: COMPARATOR
Intervention: Control group (restricted visitation)
Number of subjects: 60
Study 30659553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence examination using OralID
Number of subjects: 98
Study 30659553 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral examination under white light
Number of subjects: 98
Study 28112412 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach support including an online forum, email, and telephone support
Number of subjects: 241
Study 28112412 — intervention group
Group type: COMPARATOR
Intervention: Usual Cognitive Stimulation Therapy control group
Number of subjects: 241
Study 25497262 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of eggs (breakfast with 2 eggs)
Number of subjects: 32
Study 22893555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl bags
Number of subjects: 41
Study 22893555 — intervention group
Group type: COMPARATOR
Intervention: Thermal mattress
Number of subjects: 41
Study 22893555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl bags (subgroup: birth weight <750 g)
Number of subjects: 41
Study 22893555 — intervention group
Group type: COMPARATOR
Intervention: Thermal mattress (subgroup: birth weight <750 g)
Number of subjects: 41
Study 21059665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice therapy (repeated application of crushed ice)
Number of subjects: 19
Study 21059665 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (not specified)
Number of subjects: 19
Study 19075297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively congruent video programming
Number of subjects: 24
Study 19075297 — intervention group
Group type: COMPARATOR
Intervention: Control video (local news program)
Number of subjects: 24
Study 16542202 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV317 (250 mg oral solution)
Number of subjects: 19
Study 16542202 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV317
Number of subjects: 19
Study 16542202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15991587 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II (Intensive Outpatient Treatment)
Number of subjects: 12
Study 15991587 — intervention group
Group type: EXPERIMENTAL
Intervention: Level III (Medically Monitored Residential Treatment)
Number of subjects: 12
Study 15991587 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 12
Study 11104556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent carboplatin (400 mg/m², administered on day 1 of a 21-day cycle for a total of 4 cycles)
Number of subjects: 130
Study 11104556 — intervention group
Group type: COMPARATOR
Intervention: Etoposide + cisplatin (EP)
Number of subjects: 130
Study 11104556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent carboplatin
Number of subjects: 130
Study 9095076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (n = 231)
Number of subjects: 476
Study 9095076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (n = 71)
Number of subjects: 476
Study 9095076 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 245)
Number of subjects: 476
Study 9095076 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 96)
Number of subjects: 476
Study 7693881 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical staging plus subtotal nodal irradiation (STNI)
Number of subjects: 578
Study 7693881 — intervention group
Group type: COMPARATOR
Intervention: Staging laparotomy plus treatment adaptation (adjuvant chemotherapy only in the 33% with negative laparotomy)
Number of subjects: 578
Study 7693881 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 578
Study 7693881 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 578
Study 7693881 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 578
Study 7693881 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 578
Study 3742458 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 100
Study 3742458 — intervention group
Group type: COMPARATOR
Intervention: Dukes' stage
Number of subjects: 100
Study 3742458 — intervention group
Group type: COMPARATOR
Intervention: Exophytic tumors
Number of subjects: 100
Study 3742458 — intervention group
Group type: COMPARATOR
Intervention: Maximal tumor dimension
Number of subjects: 100
Study 3742458 — intervention group
Group type: COMPARATOR
Intervention: Degree of differentiation (well vs poor)
Number of subjects: 100
Study 29738588 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser CCIs
Number of subjects: 600
Study 29738588 — intervention group
Group type: COMPARATOR
Intervention: Manual CCIs
Number of subjects: 600
Study 27281813 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fiber/d from SCF
Number of subjects: 28
Study 27281813 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g fiber/d from SCF
Number of subjects: 28
Study 27281813 — intervention group
Group type: COMPARATOR
Intervention: 0 g fiber/d from SCF (Control)
Number of subjects: 28
Study 27281813 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium absorption
Number of subjects: 28
Study 24698652 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% drop, one drop 2h preoperatively and four times daily postoperatively for 3 days
Number of subjects: 68
Study 24698652 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control group)
Number of subjects: 68
Study 22161746 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle treatment (medical, nutritional, physical, and psychological counseling during 3 months)
Number of subjects: 40
Study 22161746 — intervention group
Group type: COMPARATOR
Intervention: Standard care (initial advice on nutrition and physical activity by the pediatrician)
Number of subjects: 40
Study 20530957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivanissevich technique
Number of subjects: 155
Study 20530957 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauber's technique
Number of subjects: 155
Study 20530957 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal sclerotherapy
Number of subjects: 155
Study 19164819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week supervised physical activity program including aerobic, balance, and strength training
Number of subjects: 49
Study 19164819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 15265352 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs and treatments for cancer pain management
Number of subjects: 0
Study 15265352 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials (RCT)
Number of subjects: 0
Study 15265352 — intervention group
Group type: COMPARATOR
Intervention: Crossover study
Number of subjects: 0
Study 15265352 — intervention group
Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 0
Study 15265352 — intervention group
Group type: COMPARATOR
Intervention: Case-control studies
Number of subjects: 0
Study 11372012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8525
Study 9136958 — intervention group
Group type: EXPERIMENTAL
Intervention: C-VAMP (vincristine, doxorubicin, methylprednisolone, and cyclophosphamide)
Number of subjects: 204
Study 9136958 — intervention group
Group type: COMPARATOR
Intervention: VAMP (vincristine, doxorubicin, and methylprednisolone)
Number of subjects: 204
Study 9136958 — intervention group
Group type: EXPERIMENTAL
Intervention: C-VAMP with verapamil
Number of subjects: 204
Study 9136958 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (C-VAMP and VAMP)
Number of subjects: 204
Study 8009094 — intervention group
Group type: EXPERIMENTAL
Intervention: High perception of illness threat
Number of subjects: 1982
Study 3068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin DHE
Number of subjects: 62
Study 3068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate normovolaemic haemodilution (haematocrit = 30%)
Number of subjects: 62
Study 3068936 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 31315420 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week (10-contact-hour), small-group, cervical health literacy (CHL) program
Number of subjects: 133
Study 29634749 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic non-specific low back pain (CNLBP) patients
Number of subjects: 24
Study 29634749 — intervention group
Group type: COMPARATOR
Intervention: Symptom-free controls (CG)
Number of subjects: 24
Study 27038614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACERTO protocol (n = 15): 6 h preoperative fasting for solids, oral drink (200 mL of 12.5% maltodextrin) up to 2 h before anesthesia, restricted intravenous fluids (1000 mL of crystalloid fluid after surgery), preoperative immune nutrition (600 mL/day of Impact - Nestlé, Brazil) for five days prior to surgery
Number of subjects: 32
Study 27038614 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (n = 17; control group): 6-8 h preoperative fasting, intravenous hydration until the 1st postoperative day, no preoperative immune supplementation
Number of subjects: 32
Study 25627292 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence‐based program delivered in three 12‐week sessions including exercise and project‐based activities, done as individuals and in groups.
Number of subjects: 186
Study 23547084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers
Number of subjects: 1968
Study 23547084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers with BRAF wild-type
Number of subjects: 1968
Study 23547084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers with KRAS mutated
Number of subjects: 1968
Study 23547084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers with KRAS wild-type
Number of subjects: 1968
Study 23547084 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1968
Study 20878857 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Making intervention (MMi)
Number of subjects: 24
Study 20878857 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 18338177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy
Number of subjects: 105
Study 18338177 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy
Number of subjects: 105
Study 16377115 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM)
Number of subjects: 0
Study 12816726 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-expert review
Number of subjects: 172
Study 12816726 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus review
Number of subjects: 172
Study 12816726 — intervention group
Group type: COMPARATOR
Intervention: Institutionally diagnosed cohort
Number of subjects: 172
Study 12816726 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 172
Study 12816726 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection extent, proliferation index, and p53 expression
Number of subjects: 172
Study 12816726 — intervention group
Group type: COMPARATOR
Intervention: Different review criteria for each arm
Number of subjects: 172
Study 10923604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg twice a day
Number of subjects: 120
Study 10923604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8736463 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 63
Study 8736463 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (no treatment specified)
Number of subjects: 63
Study 1349301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg LHRH nasal spray three times daily for 4 weeks
Number of subjects: 123
Study 1349301 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 123